Recently, the myelofibrosis secondary to PV and ET prognostic model (MYSEC-PM) was introduced to assess prognosis in myelofibrosis (MF) secondary to polycythemia vera and essential thrombocythemia (post-PV and post-ET MF), replacing the International Prognostic Scoring System (IPSS) and/or Dynamic IPSS (DIPSS) that was applied for primary MF (PMF). In a cohort of 421 ruxolitinib (RUX)-treated patients (post-PV and post-ET MF: 44.2%), we evaluated the following: (1) disease phenotype, responses, and toxicity to RUX; and (2) performance of the MYSEC-PM in post-PV or post-ET MF. While the IPSS failed to correctly stratify post-PV or post-ET MF patients at diagnosis, the MYSEC-PM identified 4 risk categories projected at significantly different survival probability (P <.001). Additionally, the MYSEC-PM maintained a prognostic value in post-PV and post-ET MF also when used over time, at RUX start. Notably, the MYSEC-PM reclassified 41.8% and 13.6% of patients into a lower and higher risk category, respectively. Finally, patients at intermediate-1 risk had significantly higher spleen responses and lower hematological toxicities compared to higher risk patients. Compared to PMF, post-PV and post-ET MF presented a more hyperproliferative disease, with higher leukocyte and/or platelet count and hemoglobin levels both at diagnosis and at RUX start. Despite comparable response rates, post-PV and post-ET MF had lower rate of RUX-induced anemia and thrombocytopenia at 3 and 6 months. The study validates MYSEC-PM in post-PV and post-ET MF prognostication. Post-PV or post-ET MF represents a separate entity compared to PMF in terms of clinical manifestations and toxicity to RUX.
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study ⁎ / F. Palandri, G.A. Palumbo, A. Iurlo, N. Polverelli, G. Benevolo, M. Breccia, E. Abruzzese, M. Tiribelli, M. Bonifacio, A. Tieghi, A. Isidori, B. Martino, N. Sgherza, M. D'Adda, M. Bergamaschi, M. Crugnola, F. Cavazzini, C. Bosi, G. Binotto, G. Auteri, R. Latagliata, A. Ibatici, L. Scaffidi, D. Penna, D. Cattaneo, F. Soci, M. Trawinska, D. Russo, A. Cuneo, G. Semenzato, F. Di Raimondo, F. Aversa, R.M. Lemoli, F. Heidel, M.L.B. Reggiani, D. Bartoletti, M. Cavo, L. Catani, N. Vianelli. - In: SEMINARS IN HEMATOLOGY. - ISSN 0037-1963. - 55:4(2018 Oct), pp. 248-255. [10.1053/j.seminhematol.2018.05.013]
|Titolo:||Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study ⁎|
|Parole Chiave:||myelofibrosis; risk scores; IPSS; MYSEC-PM; ruxolitinib|
|Settore Scientifico Disciplinare:||Settore MED/15 - Malattie del Sangue|
|Data di pubblicazione:||ott-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1053/j.seminhematol.2018.05.013|
|Appare nelle tipologie:||01 - Articolo su periodico|